RLAYRelay Therapeutics, Inc.
$17.88+284% 1Y
$17.88
$4.3852 weeks$20.77
The financials
Relay Therapeutics, Inc. by the numbers
Relay Therapeutics, Inc. (RLAY) reported revenue of $350K in Q2 2026 (quarter ended Jun 30, 2026), down 48% from the same quarter a year earlier. That came with net loss of $84M. For the full year FY2025, revenue was $15M (+53% year on year) and net income −$276M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $350K | $677K | −48% |
| Operating income | −$91M | −$77M | n/a |
| Net income | −$84M | −$70M | n/a |
| Diluted EPS | −$0.41 | −$0.41 | n/a |
On our screens:Most shorted stocks